Tirzepatide (GLP-1/GIP Dubbele Agonist) — 5mg

Tirzepatide is the first dual GIP/GLP-1 receptor agonist — it works via two complementary incretin mechanisms simultaneously. Active ingredient of Mounjaro® (diabetes) and Zepbound® (obesity), both FDA approved. Each vial contains 5mg of lyophilized Tirzepatide, ≥99% purity, HPLC tested. Tirzepatide activates both the GLP-1 receptor and the GIP (Glucose-Dependent Insulinotropic Polypeptide) receptor. Synergistic activation of both receptors leads to superior weight reduction compared to single GLP-1 agonists such as Semaglutide. In the SURMOUNT-1 phase III clinical trial Tirzepatide 15mg/week achieved a mean 20.9% weight loss — the highest ever reported for a medication. In research protocols Tirzepatide is dosed weekly subcutaneously, starting at 2.5mg/week with gradual titration to 5–15mg/week. Half-life approximately 5 days. Reconstitution with bacteriostatic water required. For laboratory and research purposes only.

Post Cycle Therapy (PCT) is not required after Tirzepatide use.